Wpływ chirurgicznego leczenia rozejścia linii szwu mechanicznego u chorych po zabiegu ominięcia żołądka sposobem Roux na gospodarkę węglowodanową oraz stężenia hormonów jelitowych &#8212; badanie wstępne by Durczynski, Adam et al.
7Prace oryginalne/original PaPers
Endokrynologia Polska
Tom/Volume 64; Numer/Number 1/2013
ISSN 0423–104X
Adam Durczynski M.D. Ph.D., Department of General and Transplant Surgery, Medical University of Lodz, Barlicki University Hospital,  
Kopcinskiego St. 22, Lodz 90–153, Poland; tel.: +48 606 222 710; +48 42 679 10 91; e-mail: A.Durczynski@interia.pl
The impact of the repair of staple line dehiscence  
in post-RYGB patients on glucose homeostasis  
and gut hormones — a preliminary study
Wpływ chirurgicznego leczenia rozejścia linii szwu mechanicznego u chorych  
po zabiegu ominięcia żołądka sposobem Roux na gospodarkę węglowodanową 
oraz stężenia hormonów jelitowych — badanie wstępne
Adam Durczynski1, Dariusz Szymanski1, Michal Nowicki1, Piotr Hogendorf1,  
Katarzyna Wojciechowska-Durczyńska2, Leszek Czupryniak3, Janusz Strzelczyk1
1Department of General and Transplant Surgery, Barlicki University Hospital, Medical University, Lodz, Poland 
2Department of Endocrinology and Metabolic Disease, Polish Mother’s Memorial Hospital, Research Institute,  
Medical University, Lodz, Poland 
3Department of Internal Medicine and Diabetology, Barlicki University Hospital, Medical University, Lodz, Poland
Abstract
Introduction: Staple-line disruption (SLD) following Roux-en-Y gastric bypass (RYGB) results in weight regain. This study evaluated 
glucose homeostasis and gut hormonal changes following surgical repair of gastrogastric fistula. 
Material and methods: Three patients with SLD underwent an oral 75 g glucose tolerance test (OGTT) before (baseline) and one week 
after gastric pouch restoration. Plasma glucose, insulin and glucagon glucose-dependent insulinotropic polypeptide (GIP) and glucagon-
like peptide–1 (GLP-1) were measured in the OGTT samples. Fasting plasma levels of ghrelin and leptin were assessed. 
Results: Restoration of gastric pouch provided moderate amelioration of glucose metabolism and gut hormones, yet without complete 
normalisation of glucose homeostasis at one week after surgery. Duodenal passage exclusion resulted in early improvement of control 
fasting plasma glucose with decrease of glucagon from 18.5 to 15 (ng/mL, by 19%), relatively stable insulin and decline of incretin hormones 
(GIP and GLP-1). Post-challenge measurements confirmed amelioration of glycaemic control with decrease of plasma glucose from 182 to 
158 mg/dL at 60 minutes. Surgical re-intervention resulted in exacerbation of GIP response with brisk rise in plasma level, accompanied 
by considerable increase of peak insulin concentration. The overall post-challenge glucagon and GLP-1 responses were decreased. Marked 
decrease in fasting plasma ghrelin and leptin were observed.
Conclusions: Our report gives further insight into the hormonal mechanisms underlying the effects of surgically altered anatomy of dif-
ferent parts of the small intestine on glucose homeostasis that is highly important, since it may facilitate novel conservative therapies of 
diabetes without the need for surgery. (Endokrynol Pol 2013; 64 (1): 7–12)
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Streszczenie
Wstęp: Rozejście linii szwu mechanicznego (SLD) po operacji ominięcia żołądka sposobem Roux (RYGB) skutkuje nawrotem otyłości. 
W badaniu poddano ocenie zmiany gospodarki węglowodanowej oraz stężeń hormonów jelitowych po chirurgicznym leczeniu przetoki 
żołądkowo-żołądkowej.
Materiały i metody: Trzech chorych z SLD poddano doustnemu testowi obciążenia 75 g glukozy (DTOG) przed oraz jeden tydzień po 
zabiegu odtworzenia proksymalnego zbiornika żołądkowego. W próbkach krwi pobranych podczas DTOG oceniano osoczowe stężenie 
glukozy, insuliny, glukagonu, insulinotropowego peptydu zależnego od glukozy (GIP) oraz glukagonopodobnego peptydu 1 (GLP-1). 
We krwi pobranej na czczo oceniano dodatkowo stężenie greliny oraz leptyny. 
Wyniki: Odtworzenie proksymalnego zbiornika żołądkowego prowadzi do umiarkowanej poprawy metabolizmu glukozy oraz stężeń 
hormonów jelitowych, jednakże bez całkowitej normalizacji homeostazy węglowodanowej w jeden tydzień od zabiegu operacyjnego. 
Wyłączenie pasażu dwunastniczego skutkowało wczesną poprawą kontroli stężenia glukozy na czczo, ze spadkiem stężenia glukagonu 
z 18,5 do 15 (ng/ml, o 19%), względnie stałym stężeniem insuliny oraz spadkiem stężeń hormonów inkretynowych (GIP i GLP-1). Pomiary 
dokonane po obciążeniu glukozą potwierdziły poprawę kontroli glikemii ze spadkiem osoczowego stężenia glukozy z 182 do 158 mg/dl 
w 60 minucie testu. Zabieg chirurgiczny skutkował nasileniem sekrecji GIP z wyraźnym wzrostem osoczowego stężenia tego hormonu 
po obciążeniu glukozą, z towarzyszącym znacznym wzrostem najwyższego stężenia insuliny. Całkowite stężenie glukagonu oraz GLP-1 
po obciążeniu glukozą malało. Zaobserwowano znaczny spadek stężenia greliny oraz leptyny na czczo.
Wnioski: Praca pozwala na dalsze poznanie mechanizmów hormonalnych leżących u podstaw wpływu chirurgicznie zmienionej anatomii 
różnych części jelita cienkiego na homeostazę węglowodanową. Poznanie tych mechanizmów jest bardzo istotne z punktu widzenia kli-
nicznego, gdyż w przyszłości może przyczynić się do wprowadzenia nowych metod leczenia zachowawczego cukrzycy, bez konieczności 
wykonywania operacji bariatrycznych. (Endokrynol Pol 2013; 64 (1): 7–12)
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Introduction
Bariatric surgery has become the therapy of choice for 
morbid obesity. One of these procedures, Roux-en-Y gastric 
bypass (RYGB), has been found to be equally effective in 
achieving substantial and durable weight loss as well as in 
amelioratingobesity-related co-morbidities including type 
2 diabetes mellitus (T2DM) [1, 2] and other concomitant 
disorders [3]. The remarkable improvement in glucose 
control is usually linked to the postoperative reduction of 
body mass. However, this beneficial effect does not depend 
on weight loss alone [4]. In most patients, hypoglycaemic 
medications are already not required soon after surgery [5]. 
The underlying mechanism of this immediate metabolic 
effect is still unknown.
Several studies have proved that a duodenal switch 
provides superior resolution of diabetes compared to a 
gastric bypass. It has been suggested that surgical exclu-
sion of specific parts of the gastrointestinal tract from 
passage of the nutrients is one of the possible reasons 
for that effect [6].
Despite the vast research in this area, we still cannot 
explain the differences in gut hormones influence on 
the final result of various bariatric procedures. 
Staple-line disruption (SLD) is a common com-
plication of vertical banded gastroplasty, while gas-
trogastric fistula following gastric bypass is a rare 
entity [7]. 
Following uncomplicated RYGB, duodenal exclu-
sion results in nutrients passing through the gastric 
pouch and directly entering the previously created 
Roux jejunal loop. SLD results in opening an alter-
native way through the remnant of the stomach, 
duodenum and first loops of jejunum. As a result, 
it can lead to preoperative eating habits and weight 
regain. Surgical revision with restoration of gastric 
pouch is indicated (Fig. 1).
In an attempt to better understand the physiologi-
cal factors underlying response to bariatric surgery, we 
herein report our study of glucose homeostasis and 
hormonal changes following surgical repair of gastro-
gastric fistula.
Figure 1. Before — Preoperative two routes passage (Roux loop and alternative way through the remnant of the stomach, duodenum 
and first loop of jejunum). After — Postoperative Roux loop passage (after restoration of gastric pouch and duodenal exclusion)
Rycina 1. Przed — przedoperacyjne dwie drogi pasażu (pętla Roux oraz alternatywna droga przez żołądek, dwunastnicę i pierwszą 
petlę jelita cienkiego). Po —pooperacyjny pasaż przez pętlę Roux (po odtworzeniu proksymalnego  zbiornika żołądkowego z wyłączeniem 
pasażu dwunastniczego)














Among the patients investigated in the Department of 
General and Transplant Surgery of the Medical Uni-
versity in Lodz, Poland for weight regain following 
Roux-en-Y gastric bypass performed for morbid obesity, 
three subjects with endoscopically confirmed staple-line 
dehiscence were found. All of them were consented for 
surgery and operated on. On laparotomy, the restora-
tion of gastric pouch was performed by transection of 
the stomach just below the staple line. 
Patient characteristics are summarised in Table I. 
Each subject underwent an oral 75 g glucose toler-
ance test (OGTT) before (baseline) and one week 
after the surgery. Blood samples were centrifuged 
immediately at 3,000 rpm for ten minutes and stored 
at –80°C until assayed. Samples from our patients 
obtained before and after surgery were studied using 
the same commercial kits. Plasma glucose, pancreatic 
hormones (insulin and glucagon), small intestine in-
cretin hormones (glucose-dependent insulinotropic 
polypeptide, GIP and glucagon-like peptide 1, GLP-1) 
were measured in the OGTT samples. Fasting plasma 
levels of appetite regulating hormones (ghrelin and 
leptin) were assessed before and after surgical re-
intervention. All data is given in text and tables. 
Results
The data from the three individual studied patients is 
shown in Tables II and III. Generally, duodenal pas-
sage exclusion in the studied group resulted in early 
improvement of control fasting plasma glucose with 
decrease of glucagon from 18.5 to 15 (by 19%), relatively 
stable insulin (Fig. 2) and decline of incretin hormones 
(GIP and GLP-1; Table IV). Post-challenge measure-
ments confirmed amelioration of glycaemic control 
with decrease of plasma glucose from 182 to 158 mg/dL 
at 60 minutes (Fig. 2). Surgical re-intervention resulted 
in exacerbation of GIP response with a brisk rise in 
plasma level (Table IV), accompanied by a considerable 
increase of peak insulin concentration (Fig. 2). On the 
contrary, the overall post-challenge glucagon and GLP-1 
responses were decreased. After gastric pouch restora-
tion, a marked decrease in fasting plasma ghrelin and 
leptin were observed (Table II).
Table I. Clinical characteristics of the patients included in the study
Tabela I. Charakterystyka kliniczna chorych zakwalifikowanych do badania










Actual BMI  
[kg/m2] 
1 F 54 2003 56.79 32.45 2011 (eight years 
postoperatively) 
44.62 34.13
2 M 51 2007 54.84 33.3 2010 (three years 
postoperatively) 
49.86 27.7 
3 M 46 2003 36.75 23.38 2011(eight years 
postoperatively) 
34.41 27.73
Table II. Glucose, glucagon, insulin, GIP and GLP-1 plasma concentrations of studied individuals in oral glucose tolerance 
test before (baseline) and one week after surgery
Table II. Stężenia glukozy, glukagonu, insuliny i GLP-1 w osoczu badanych osób oceniane w doustnym teście obciążenia 
glukozą przed (wartość wyjściowa) i tydzień po operacji
Factor Glucose [mg/dL] Glucagon [ng/mL] Insulin [IU/mL] GIP [ng/mL] GLP-1 [ng/mL]
OGTT minute 0 60 120 0 60 120 0 60 120 0 60 120 0 60 120
Patient 1 Baseline 120 182 156 19.7 17.9 9.4 11.4 79.9 51.8 1.44 1.39 0.56 2.5 45.6 62.4
One week 118 133 168 19 18.9 1.6 11.1 106.8 21.4 0.9 1.28 1.1 2.2 58.6 53.4
Patient 2 Baseline 113 216 165 23.3 8.3 9.2 5 61.5 50.1 2.1 0.75 1.1 1.3 92.3 98.5
One week 104 211 157 15.7 6.3 8.9 4.8 78 43.7 1.9 3.8 1.5 0.8 26.6 36.7
Patient 3 Baseline 119 148 106 12.5 11.2 13.1 5.6 23.9 25.7 1.37 1.2 0.7 3.5 121 162.7
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Discussion
The main focus of this report is the comparison of 
glucose homeostasis before and after surgical re-
intervention in IFG patients with SLD. Our study sug-
gests that restoration of gastric pouch provides very 
early, moderate amelioration of glucose metabolism 
with improvement of fasting glucose level control and 
post-challenge glucose tolerance, yet without complete 
normalisation of glucose homeostasis at one week after 
surgery. Likewise, other authors [5] have indicated that 
marked improvement may occur very soon after bari-
atric surgery before significant weight loss. Neverthe-
less, there has been little assessment of the hormonal 
background of these changes shortly after surgically 
altered anatomy of different parts of the small intestine. 
By studying patients with SLD before and one 
week after surgery, we found that duodenal exclusion 
resulted in a decrease of fasting level and exagger-
ated postprandial GIP response compared to the two 
routes passage (duodenal limb and Roux loop). The 
changes seen in this hormone after bariatric surgery 
are not consistent in the literature. Most reports 
have indicated that fasting [8], but also postprandial, 
GIP levels reduce after malabsorptive surgery [9], 
and only a few studies have reported an increase of 
glucose-stimulated GIP levels [10], likewise in our 
report. Some authors indicate that a decrease in GIP 
after a bariatric operation is beneficial [11]. This seems 
to be untrue, given the data on its glucose-dependent 
manner of stimulating insulin secretion. Postprandial 
insulin secretion improves rapidly after surgery [12], 
something also proven by our study. It occurs almost 
too immediately, and cannot to be explained by the 
weight loss. Our study suggests that surgically altered 
anatomy of foregut affects glucose homeostasis by 
Table III. Fasting ghrelin and leptin plasma concentrations 
of studied individuals before (baseline) and one week after 
surgery
Tabela III. Stężenia na czczo greliny i leptyny w osoczu 
krwi badanych osób, przed (wartość wyjściowa) i tydzień 
po operacji
Factor Timepoint Ghrelin [ng/mL] Leptin [ng/mL]
Patient 1 Baseline 58.6 30.98
One week 47.4 28.83
Patient 2 Baseline 95.6 31.93
One week 17.9 22.8
Patient 3 Baseline 25.15 30.53
One week 18.2 24.13
Figure 2. A. Glucose (mg/dL); B. Glucagon (ng/mL) and C. 
Insulin (IU/mL) mean plasma concentrations (± standard 
deviations) in oral glucose tolerance test before (baseline) and one 
week after surgery
Rycina 2. Średnie stężenia A. glukozy (mg/dl); B. glukagonu 
(ng/ml) i C. insuliny w osoczu krwi (± odchylenie standardowe) 
oceniane w doustnym teście obciążenia glukozą (wartość 















































GIP concentrations changes. Given that GIP triggers 
insulin secretion, it is possible that enhanced secretion 
of this incretin, rather than reducing insulin resist-
ance, contributes to exaggerated postprandial insulin 
response in these subjects. 
Numerous studies have reported that improve-
ment in glucose tolerance after bariatric surgery is 
related to the increase of GLP-1 response [13]. In 
contrast, other reports have failed to show these dis-
crepancies in fasting GLP-1 in the very short period 
after RYGB [14], although only fasting samples were 
measured. 
In our study, we found that gastric pouch restora-
tion in patients with SLD is associated with a decrease 
of GLP-1 secretion. This is entirely contradictory to 
most reports on hormonal changes after bariatric 
surgery [13], although, in these studies, a liquid test 
meal was used as the best manner of eliciting robust 
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responses of this incretin hormone [15]. Therefore, 
one might speculate whether our data is limited by 
nutrition-related bias, since consistent responses of 
GLP1 in T2DM were observed using meal tests but not 
glucose tolerance tests [16]. Furthermore, only control 
tests after primary RYGB in our patients would have 
clearly showed that the observed GLP-1 decrease is 
specific for gastric pouch restoration in patients with 
SLD. Thus, further studies are needed to elucidate 
these controversies. So far, it has been proved that 
in contrast to uncomplicated gastric bypass, purely 
gastric restrictive procedures are not associated with 
any changes in GLP-1 levels.
To date, as in our study, it has been found that 
elevated plasma glucagon markedly decreases in se-
verely obese patients after gastric bypass [17]. This ob-
servation may be of physiological significance, since 
fasting hyperglucagonaemia and blunted response 
of glucagon are contributory to T2DM and may lead 
to fasting and postprandial hyperglycaemia. Future 
studies will be required to determine the specific role 
of the glucagon decrease and diabetes resolution after 
bariatric surgery. 
Circulating ghrelin correlates inversely with body 
mass index (BMI) [18], but still the question as to 
whether the weight loss effect of RYGB depends on 
this hormone alterations requires to be clarified. Acute 
early decline in ghrelin levels, likewise in our subjects 
with diversion from two to one route passage, could 
be related to either intraoperative interference of the 
fundic vagal supply [19] or ‘override suppression’ of 
ghrelin-producing cells isolated from contact with 
enteral nutrients [20]. Several other groups have 
found that reduction in ghrelin is temporary, and that 
subsequently it tends to further increase above pre-
operative levels, indicating no relationship between 
changes of ghrelin signalling and weight loss after 
RYGB [21]. These discrepant results call for further 
elucidation.
Leptin concentration has been found to be decreased 
in obese patients after various bariatric surgeries [21], 
since it usually reflects the total amount of fatty tissue in 
the body. BMI is the main determinant of the decrease of 
serum leptin concentration long-term after surgery. The 
results of our subjects indicate that a significant decline 
of leptin occurs soon after surgical reintervention in 
SLD patients. This is consistent with previous knowl-
edge that leptin might be regulated by a mechanism of 
foregut passage alterations with exclusion of duodenal 
limb. Early normalisation of leptin may induce further 
weight loss and glucose homeostasis improvement, with 
resolution of insulin resistance [8].
We acknowledge several limitations of our study. 
Firstly, as mentioned, we used a 75 g oral glucose toler-
ance test. The dynamic of gastrointestinal hormones 
response including incretins following this test is dif-
ferentiated in various studies and might not be repre-
sentative. Furthermore, major abdominal surgery may 
cause early, marked glucose homeostasis disturbances 
including stress hyperglycaemia that may obscure hor-
monal changes related to alteration of the small intestine 
anatomy. Nevertheless, our results went exactly in the 
opposite direction, with moderate amelioration of the 
glucose metabolism.
Table IV. Changes of GIP and GLP-1 plasma concentrations in oral glucose tolerance test and fasting plasma ghrelin and leptin 
before (baseline) and one week after surgery. Values are means plus or minus standard deviations
Tabela IV.  Zmiany stężeń GIP i GLP-1 w osoczu krwi ocenianych w doustnym teście obciążenia glukozą oraz stężeń na czczo 
greliny i leptyny przed (wartość wyjściowa) i tydzień po operacji. Wyniki przedstawiono jako wartości średnie z odchyleniem 
standartowym
Factor Time OGTT samples mean plasma levels ± SD
0 min 60 min 120 min
GIP [ng/mL] Baseline 1.63 ± 0.4 1.11 ± 0.32 0.78 ± 0.28
One week 1.22 ± 0.58 2.06 ± 1.50 1.46 ± 0.34
GLP-1 [ng/mL] Baseline 2.43 ± 1.1 86.3 ± 38.05 80.9 ± 50.8
One week 1.93 ± 1.02 53.2 ± 24.3 67.03 ± 38.98
Fasting mean plasma levels ± SD
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Conclusions
Our report gives further insight into the hormonal 
mechanisms underlying the effects of bariatric surgery 
on glucose homeostasis that is highly important, since 
it may facilitate novel conservative therapies of diabetes 
without the need for surgery.
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